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discounted at 5% annually. Sensitivity analyses were performed. Results: Fenofibrate 
monotherapy improved mean quality-adjusted life expectancy by 0.09 QALYs versus 
placebo due to fenofibrate patients spending more time in mild DR states. Direct medi-
cal costs were AUD 898 higher for fenofibrate monotherapy, with additional treatment 
costs partially offset by reduced cost associated with advanced DR (e.g. ophthalmolo-
gist time and laser treatment), leading to an ICER of AUD 10,221 per QALY gained. 
Similarly, fenofibrate+statin led to an improvement of 0.05 QALYs versus statin alone 
with an incremental direct cost of AUD 1,707. The ICER for fenofibrate+statin was AUD 
33,350 per QALY gained versus statin alone. Sensitivity analysis showed that results 
were relatively insensitive to changes in a range of assumptions. ConClusions: The 
reduced risk of DR progression associated with fenofibrate treatment was projected 
to improve quality-adjusted life expectancy, with treatment costs partially offset by 
reduced costs of retinopathy care. ICERs indicated that fenofibrate therapy was in the 
range likely to be considered cost-effective in Australia.
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objeCtives: Insulin degludec (IDeg) is a basal insulin with an ultra-long dura-
tion of action for the management of patients with type 1 (T1DM) and patients 
with type 2 (T2DM) diabetes. IDeg has demonstrated effective blood glucose con-
trol with less hypoglycaemic events and with an option for flexibility in dose time 
compared to insulin glargine (IGlar). The aim of this analysis was to evaluate the 
cost-effectiveness of IDeg versus IGlar in adults with T1DM in the UK. Methods: 
Meta-analysis data from two phase III clinical studies were used to populate a 
simple, transparent short-term model. The analysis was conducted from the UK 
National Health Service perspective and costs and benefits were calculated over 
a 12-month period. Sensitivity analyses were conducted to assess the degree of 
uncertainty around the results. In order to test the robustness of the results, two 
versions of the model were used. One applied disutilities derived from the SF-36 
questionnaire used in the clinical trials, the other applied disutilities associated with 
the occurrence of hypoglycaemic events. In both approaches an additional utility 
gain was attributed to the benefit of dosing flexibility. Baseline incidence of hypogly-
caemia was taken from a real-life study from the UK. Resource use associated with 
hypoglycaemia was documented in the clinical trials. Published tariffs were used 
as unit costs. Results: The base-case ICERs were £12,637/QALY and £13,349/QALY 
in the two modelling approaches, which are below commonly accepted thresholds 
for cost-effectiveness. The results were robust and largely insensitive to changes in 
input parameters. ConClusions: This short-term modelling approach allows the 
economic evaluation of newer insulin analogues when advanced long-term model-
ling based on HbA1c differences is inappropriate due to the treat-to-target nature of 
the clinical trials resulting in equivalent HbA1c levels. For patients in the UK with 
T1DM IDeg is a cost-effective treatment option compared with IGlar.
PDB65
Cost-EffECtivEnEss of insulin DEgluDEC ComParED with insulin 
glarginE for PatiEnts with tyPE 2 DiaBEtEs mEllitus initiating 
insulin thEraPy in thE unitED KingDom
Evans M.1, Chubb B.2, Christensen T.3, Gundgaard J.3, Wolden M.3
1University Hospital Llandough, Cardiff, UK, 2Novo Nordisk Ltd., Crawley, UK, 3Novo Nordisk A/S, 
Søborg, Denmark
objeCtives: Insulin degludec (IDeg) is a basal insulin with an ultra-long dura-
tion of action for management of patients with type 1 (T1DM) and patients with 
type 2 (T2DM) diabetes. IDeg has demonstrated effective blood glucose control with 
less hypoglycaemic events and an option for flexibility in dose time compared to 
insulin glargine (IGlar). The aim of this analysis was to evaluate the cost-effec-
tiveness of IDeg versus IGlar in adults with T2DM initiating insulin therapy in the 
UK. Methods: Meta-analysis data from three clinical studies were used to populate 
a 1-year cost-utility model. The analysis was conducted from the UK National Health 
Service perspective. Sensitivity analyses were conducted to assess the robustness 
of results. Two versions of the model were tested, one applied disutilities derived 
from the SF-36 questionnaire used in the clinical trials, the other applied disutili-
ties associated with the occurrence of hypoglycaemic events. In both approaches 
an additional utility gain was attributed to the benefit of dosing flexibility. Baseline 
incidence of hypoglycaemia was derived from a UK real-life study. Resource use 
associated with hypoglycaemia was documented in the clinical studies. Official 
tariffs were used as unit costs. Results: Base-case ICERs were £15,705/QALY and 
£13,003/QALY in the two modelling approaches. Results were robust, with baseline 
rate of hypoglycaemia a key driver of results. Using hypoglycaemia rates from a 
subgroup of patients who experienced ≥ 1 hypoglycaemic event per year IDeg was 
highly cost-effective versus IGlar; with estimated ICERS of £4,706/QALY and £2,528/
QALY. ConClusions: This short-term modelling approach allows the economic 
evaluation of newer insulin analogues when advanced long-term modelling based 
on HbA1c differences is inappropriate due to treat-to-target trial design. For patients 
with T2DM on a basal-only insulin regimen, IDeg is cost-effective compared with 
IGlar and offers additional benefits to subgroups of patients, such as those suffering 
from recurrent hypoglycaemia.
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tively). ConClusions: Patients treated with CANA in dual therapy experienced an 
additional 0.21 QALYs over 40 years versus patients treated with GLIM. The primary 
drivers were improved weight while on agent and fewer hypoglycaemic events.
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objeCtives: In Poland, where long acting insulin analogues (LAA) are not currently 
reimbursed in T2DM, it is crucial to select a group of patients for whom LAA may 
be particularly preferred. Based on NICE recommendation such patients are those 
treated with human insulin (NPH) but not achieving glycaemic control. Thus the aim 
of this study was to evaluate the cost-effectiveness of insulin detemir (IDet) when 
compared to NPH in subpopulation of poorly controlled T2DM as defined by HbA1c 
≥ 8% and/or ≥ 1 episode of severe or nocturnal hypoglycemia recorded during ≥ 6 
months of NPH treatment. Methods: A validated computer simulation of diabetes 
model (IMS-CORE) was used to project long-term clinical and economic outcomes. 
Clinical effects in HbA1c improvement, BMI change and reduction in hypoglycemic 
episodes were modelled. Analysis was based on findings from the subgroups of the 
PREDICTIVE study – a real-world data trial – that closely reflects the defined target 
population. Two distinct insulin therapy regimens with IDet and NPH were evalu-
ated: basal-supported oral therapy (BOT) and a basal-bolus (BB) regimen. Baseline 
cohort characteristics, disease progression and utility estimates were obtained from 
systematic literature review. Costs were obtained from Polish published data. The 
analysis was conducted from a public payer and patient perspective over a lifetime 
time horizon. Discount rates were 5% (costs) and 3.5% (outcomes). Results: The 
mean QALY gain resulting from treatment initiation with IDet compared with NPH 
was 0,311 (BOT) and 0,451 (BB). Base-case incremental cost-effectiveness ratios 
(ICERs) were 38,136 PLN/QALY (9,113€ ) and 13,726 PLN/QALY (3,280€ ), respectively. 
At the current ICER threshold of 105,801 PLN/QALY (25,281€ ) in Poland, probability 
of IDet being cost-effective compared to NPH is 95% (BOT) and approaching 100% 
(BB). ConClusions: Based on generally accepted cost/QALY threshold values in 
the Polish settings, IDet was found to be a cost-effective option for T2DM patients 
with inadequately controlled diabetes.
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objeCtives: Insulin degludec (IDeg) is a basal insulin with an ultra-long duration 
of action for management of patients with type 1 (T1DM) and patients with type 
2 (T2DM) diabetes. IDeg have demonstrated efficacious blood glucose control with 
less hypoglycaemic events and with an option for flexibility in dose time compared 
insulin glargine (IGlar). The objective was to assess the cost-effectiveness of IDeg in 
Spain, compared with IGlar. The analysis focused on subgroups of patients within 
three treatment regimens: T1DM, T2DM treated with basal insulin in combination 
with oral anti-diabetics (BOT) and T2DM treated with basal-bolus (BB). Methods: 
A one-year cost-utility model driven by differences in hypoglycaemia was used. Two 
alternative utility approaches were used: in the first case, the utility gain was elicited 
from the clinical trials. In the second, published dis-utilities for hypoglycaemic 
events and self-monitoring blood glucose tests were used to calculate QALYs. Cost 
and utilities were also estimated for potential use of less blood glucose test strips. 
Three subgroups were analysed: those using twice daily IGlar, those with high risk 
of severe hypoglycaemia, and those obtaining extra utility from dosing flexibility. 
Unit costs pertained to public tariffs and reflected the payer perspective. Baseline 
incidence rates of hypoglycaemia and related resource use was derived from a 
Spanish observational study. Results: IDeg was dominant for T1DM, T2DM BOT 
and T2DM BB switching from twice daily. T2DM BOT with high risk of hypoglycaemia 
was also dominant. As for patients benefiting from dosing flexibility the cost/QALY 
were 6,921€ /QALY in T1DM, 9,244€ /QALY in T2DM BOT, and 33,099€ /QALY in T2DM 
BB. The use of the two different utility methods gave similar results. Univariate and 
probabilistic sensitivity analyses confirmed robust results. ConClusions: This 
analysis demonstrates that IDeg is a cost-effective option in Spain, when used in 
sub-groups of patients currently treated with long-acting insulin.
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objeCtives: Evidence from the landmark trials FIELD and ACCORD demonstrated 
that fenofibrate significantly reduces rates of diabetic retinopathy (DR) progression 
in type 2 diabetes patients (T2DM). This study evaluates the long-term cost-effective-
ness of fenofibrate mono- and combination therapy for DR in Australia. Methods: A 
seven-state Markov model simulated progression of DR based on data from the Blue 
Mountain Eye Study. Risk reductions for retinopathy progression were derived from 
FIELD for fenofibrate monotherapy (vs. placebo) and ACCORD for fenofibrate+statin 
(vs. statin alone). No additional benefits were assumed beyond 5 years (DR progression 
was the same with/without fenofibrate after year 5). Quality-adjusted life expectancy, 
direct costs and incremental cost-effectiveness ratios (ICERs) were reported over 10 
years. Unit costs (2012 Australian dollars, AUD), resource use and utilities were taken 
from country-specific sources/expert opinion. Future costs and clinical benefits were 
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objeCtives: Foot ulceration is a major cause of disability in diabetic patients. 
Disability of patients with diabetic foot ulceration (DFS – Diabetic Foot Syndrome) 
concerns not only patients themselves, but also the informal caregivers, mainly 
their close relatives. The aim of this study was to estimate lost productivity in 
a population of family caregivers of patients with diabetic foot ulceration in 
Poland. Methods: A survey among 189 patients with DFS (treated in ambulatory 
care) and their families was conducted. To assess the impact of diabetic ulceration 
on productivity of caregivers to DFS patients the modified questionnaire WPAI-CG 
was used. The PEDIS scale was used to classify severity of ulceration. Results: A 
total of 116 out of 189 questionnaires were collected, and data on 93 responders 
(25 males) were included in the analysis (23 questionnaires were returned empty 
or concluded that informal care is not provided to DFS patients). Fifty-two (13 
males) out of 93 caregivers were employed at the time of the survey. Mean age 
of the population of caregivers was 45.9±11.2 years. Most were close relatives of 
DFS patients (58% spouses, 27% children). Almost half caregivers were employed 
in private sector (46%). Most had higher (50%) or secondary (48%) education. The 
average weekly work time declared was 40.4±13.1 hours. Approximately 70% of 
caregivers were urban population. The average percentage of work time missed 
and the percentage of working impairment while working due to informal care 
of DFS patients were estimated at 11.9% and 25.0%, respectively. The percentage 
of overall work impairment due to informal care of DFS patients was 32.2%. This 
amounts to weekly average time of the absence of 13.0 hours. ConClusions: 
The lost productivity due to informal care on DFS patients is substantial and may 
have important implications for the economy.
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objeCtives: GLP-1 agonists in combination with basal insulin (BI) have demon-
strated additional improvement of glycemic control in uncontrolled T2DM patients 
in clinical trials. It is therefore important to assess the real-world utilisation of 
GLP-1 agonists in combination with BI in T2DM patients. Methods: Retrospective 
cohort analysis (2010 to 2012) to assess GLP-1 agonist utilisation in T2DM patients 
based on the Norwegian Institute of Public Health Prescription Database (NorPD). 
Both ICPC= T90 and ICD-10= E11 were applied to identify T2DM patients. Patients 
who had ≥ 2 GLP-1 dispensed within 6-month in Year-2011, with 1-year pre-Base-
line/post- Follow-up GLP-1 initiation were included in the analysis. Baseline anti-
diabetic drug use and combination use of GLP-1 and BI at Follow-up were also 
assessed. Results: Of the 1,500 GLP-1 initiators identified (mean age= 57; 52% 
male) at Baseline, 77% were on OADs, 19% on BI, 2% on prandial insulin (no BI) 
and 2% on other/no anti-diabetic drug. During 1-year Follow-up of GLP-1 adding 
on OADs patient population, 56% used GLP-1 continuously including 50% who 
used GLP-1 alone and 6% added BI. In total, 15% had either combined with or 
switched to BI, 4 months after the first GLP-1 was dispensed. Of those GLP-adding 
on BI patient population, 53% continuously used GLP-1 including 26% had both 
GLP-1 and BI dispensed throughout the Follow-up. About 52% had either BI inter-
rupted or discontinued approximately 2 months after the first GLP-1 was dis-
pensed. In total, 27% had insulin bolus dispensed; of which 58% either interrupted 
or discontinued GLP-1. ConClusions: About 1/3 of GLP-1 initiators were in com-
bination with BI. In BI treated T2DM patients > 25% remained on both GLP-1 and 
BI, while another > 25% required treatment augmentation or switched to bolus. 
The data suggests an unmet treatment need, particularly in T2DM patients treated 
with BI.
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objeCtives: To provide a comprehensive and coherent reference document of 
published cost data for diabetic complications in France, Germany, Italy and Spain 
for use in economic diabetes modeling. Methods: A search for published cost of 
diabetes complications data from a health care payer perspective was performed 
on government websites, in peer-reviewed journals and local cost experts. All costs 
were inflated to 2013 Euros (€ ). Results: First year costs of myocardial infarction 
varied between € 3,041 in France and € 9,690 in Germany. Heart failure costs were 
similar across countries: € 3,104 in France; € 2,791 in Germany; € 4,000 in Italy and 
€ 3,316 in Spain. Costs of non-fatal stroke were higher in Germany (€ 16,441) than in 
other countries (Spain € 8,016; Italy € 6,073; France € 5,447). Everywhere, the cost of 
haemodialysis was higher than peritoneal dialysis € 35,972 versus € 21,255 in Spain, 
€ 21,552 versus € 18,485 in Italy, € 34,290 versus € 34,069 in Germany € 71,683 versus 
€ 48,752 in France. Renal transplant cost was estimated to € 84,114 in France, € 34,858 
in Germany, € 38,528 in Italy and € 26,618 in Spain. The cost of a major hypoglycemia 
requiring medical care was € 4,275 in Spain, € 2,561 in Germany, € 1,391 in Italy and 
€ 1,165 in France. Neuropathy complication costs varied widely: € 3,808 (France); 
€ 16,762 (Germany); € 4,290 (Italy); and € 5,330 (Spain) for foot ulcers and € 6,056 (Italy); 
€ 7,754 (Germany); € 9,578 (France); and € 12,118 (Spain) for lower-extremity ampu-
tation. ConClusions: This study provides a coherent set of costs for diabetes 
complications in four European countries. Due to the differences in health care 
objeCtives: Insulin degludec (IDeg) is a basal insulin with an ultra-long dura-
tion of action for management of patients with type 1 (T1DM) and patients with 
type 2 (T2DM) diabetes. IDeg has demonstrated efficacious blood glucose control, 
with less hypoglycaemic events, and with an option for flexibility in dose time, 
compared with insulin glargine (IGlar). The objective was to assess the cost-
effectiveness of IDeg in Belgium, compared with IGlar. The analysis focused on 
patients in three treatment regimens: T1DM, T2DM treated with basal insulin in 
combination with oral anti-diabetics (BOT) and T2DM treated with basal-bolus 
(BB). Methods: A one-year cost-utility model driven by differences in hypogly-
caemia was used. Published dis-utilities for hypoglycaemic events were multiplied 
by the rate of hypoglycaemia to calculate quality-adjusted life years (QALYs). Costs 
and utilities were also calculated for potential use of less blood glucose test strips. 
A utility gain was attributed to the additional benefit of dosing flexibility. Unit 
costs pertained to public tariffs and reflected the payer perspective in Belgium. 
Baseline incidence rates of hypoglycaemic events and related resource utilization 
pertained to a Belgian patient-reported outcomes study. Hospitalization costs 
following severe hypoglycaemia were estimated using the IMS Hospital Disease 
Database. Results: IDeg was associated with an incremental cost-effectiveness 
ratio of 14,677€ /QALY in T1DM, 4,976€ /QALY in T2DM BOT, and 12,930€ /QALY in 
T2DM BB. Univariate and probabilistic sensitivity analyses confirmed robust 
results. Results were most sensitive to variations in number of IGlar doses per 
day, and number of glucose-monitoring tests. At a willingness to pay threshold of 
30,000€ /QALY, IDeg would be cost-effective in 54%, 100% and 93% of the cases in the 
T1DM, T2DM BOT or T2DM BB treatment regimens respectively. ConClusions: 
These analyses demonstrate that IDeg is cost-effective in Belgium, when used 
in patients with T1DM and T2DM currently treated with long-acting insulin ana-
logues.
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objeCtives: The analysis goal is to determine the cost-effectiveness of liraglutide 
as add-on to metformin in for patients with type 2 diabetes in condition of the 
Russian health care system. Total medical expenses and effectiveness in terms of 
QALY are compared for liraglutide, glimepiride and rosiglitazone, all in combina-
tion with metformin, and metformin monotherapy. Methods: Data were sourced 
from a clinical trial comparing liraglutide vs. glimepiride (in combination with 
metformin), and a clinical trial comparing liraglutide vs. rosiglitazone (as add-on to 
metformin). From them data on clinical effectiveness in form of impact on HbA1(c), 
body mass index and blood pressure are extracted. Utility values are mostly taken 
from the UK Prospective Diabetes Studies supplemented with other published 
sources. The analysis is conducted from the perspective of the Russian health care 
system. Respectively the cost of the following resources is accounted: comparing 
of alternatives, concomitant pharmacotherapy, cost of medical manipulation, cost 
of ambulatory visits. Both future costs and clinical benefits are discounted at 3 
percent. Sensitivity analysis is performed. Results of this analysis are shown in the 
incremental cost-utility rate (ICUR). Results: The data of the analysis illustrates 
that liraglutide therapy for type 2 diabetes patients provides a significant health 
improvement from the perspective of quality adjusted life-years. Simultaneously 
liraglutide demonstrates better cost-effectiveness than the compared alternatives. 
The ICUR index of 1.2 mg liraglutide in combination with metformin equal to 1 
348368 rub, 1 161874 rub and 537331 rub for QALY in comparison with metformin 
monotherapy, glimepiride and rosiglitazone, both in combination with metformin, 
respectively. ConClusions: Liraglutide has turned to be cost-effective therapeu-
tic alternative for treatment of type 2 diabetes in adult patients in conditions of 
Russian health care system over a 10-year time horizon.
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objeCtives: To evaluate the long-term cost effectiveness of sitagliptin com-
pared to glimepiride and acarbose in the treatment of type 2 diabetes mellitus in 
China. Methods: Sitagliptin, as add-on therapy to metformin, was compared to 
glimepiride and acarbose, and as monotherapy was also compared to acarbose. 
The validated UKPDS Outcomes Model was used to estimate the direct medical 
costs and outcomes (life years and QALYs gained). The demographic characteris-
tics and clinical data were taken from published literature. The quality of life data 
was obtained from published literature and re-confirmed through a questionnaire 
survey from a clinical expert panel of 20 diabetes specialists. The cost of drugs 
was calculated based on government guidance price or actual market price. The 
annual cost of complications was estimated based on expert opinions. Patients’ 
outcomes were modeled for 40 years and incremental cost-effectiveness ratios 
were calculated. Both future costs and clinical benefits were discounted at 3 
percent. A probabilistic sensitivity analysis was performed to understand the key 
drivers and general sensitivity of the model. Results: The results showed that, 
compared to the treatment of glimepiride and acarbose plus metformin therapy, 
the add-on of sitagliptin provided a gain of 0.02 and 0.95 QALYs per patient, and 
the incremental cost-effectiveness ratios were USD 9,470 and USD 399, respec-
tively. The results also showed that compared to acarbose monotherapy (100mg 
t.i.d and 200mg t.i.d), the sitagliptin monotherapy (100mg/d and 200mg/d) was 
dominant, with higher QALYs (0.58 and 0.92) and years of life (0.72 and 1.23) 
gained and lower cost (USD 90 and USD 185). ConClusions: According to the 
China’s GDP per capita in 2011 (USD 5,674), the results demonstrate that sitag-
liptin is more cost-effective than glimepiride and acarbose in the treatment of 
diabetes mellitus in China.
